These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25768715)

  • 41. [Endocrinology and nuclear medicine aspects of the treatment of thyroid tumours].
    Vicek P
    Vnitr Lek; 2007; 53(7-8):807-11. PubMed ID: 17915423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thyroxine dosing after I131Radioiodine ablation for differentiated thyroid cancer.
    Clarke K; Gill V; Gerrard G
    Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):559-60. PubMed ID: 21530195
    [No Abstract]   [Full Text] [Related]  

  • 43. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.
    Robbins RJ; Schlumberger MJ
    J Nucl Med; 2005 Jan; 46 Suppl 1():28S-37S. PubMed ID: 15653649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma].
    Liu B; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Jun; 29(3):588-92. PubMed ID: 22826964
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Approaches to the treatment of high-risk thyroid cancer.
    Robbins J
    Thyroid; 1994; 4(3):385-7. PubMed ID: 7833681
    [No Abstract]   [Full Text] [Related]  

  • 46. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
    Mäenpää H
    Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Presentation and practical management to optimize radioiodine treatment of well differentiated thyroid cancer: ablation of thyroid remnants with radioiodine.
    Janisch A; Altenbrunn HJ; Markwardt J
    Radiobiol Radiother (Berl); 1987; 28(5):707-10. PubMed ID: 3441634
    [No Abstract]   [Full Text] [Related]  

  • 48. [Therapeutic approach to differentiated carcinoma of the thyroid gland].
    Busnardo B
    Minerva Endocrinol; 1987; 12(1):69-73. PubMed ID: 3587203
    [No Abstract]   [Full Text] [Related]  

  • 49. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma.
    Fard-Esfahani A; Emami-Ardekani A; Fallahi B; Fard-Esfahani P; Beiki D; Hassanzadeh-Rad A; Eftekhari M
    Nucl Med Commun; 2014 Aug; 35(8):808-17. PubMed ID: 24751702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Therapeutic borderline situations in papillary carcinoma of the thyroid].
    Schumann J
    Dtsch Med Wochenschr; 1977 Sep; 102(37):1324-8. PubMed ID: 902600
    [No Abstract]   [Full Text] [Related]  

  • 51. Differentiated thyroid cancer: lobectomy and radioiodine, a treatment suitable for all cases?
    Allan E; Owens SE; Waller ML
    Nucl Med Commun; 1999 Nov; 20(11):983-9. PubMed ID: 10572907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: concise communication.
    Ramacciotti C; Pretorius HT; Line BR; Goldman JM; Robbins J
    J Nucl Med; 1982 Jun; 23(6):483-9. PubMed ID: 7077401
    [No Abstract]   [Full Text] [Related]  

  • 53. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
    Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
    Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The treatment of thyroid cancer.
    Halnan KE
    Ann Radiol (Paris); 1977; 20(8):826-30. PubMed ID: 610557
    [No Abstract]   [Full Text] [Related]  

  • 55. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and
    Leboulleux S; Benisvy D; Taieb D; Attard M; Bournaud C; Terroir-Cassou-Mounat M; Lacroix L; Anizan N; Schiazza A; Garcia ME; Ghuzlan AA; Lamartina L; Schlumberger M; Godbert Y; Borget I
    Thyroid; 2023 Sep; 33(9):1124-1129. PubMed ID: 37350119
    [No Abstract]   [Full Text] [Related]  

  • 56. A worst case scenario.
    Miller KL; Eggli DF; King SH
    Health Phys; 2000 Feb; 78(2 Suppl):S16-7. PubMed ID: 10651399
    [No Abstract]   [Full Text] [Related]  

  • 57. Spindle and giant cell carcinoma of the thyroid: a different therapeutic approach.
    Rogers JD; Lindberg RD; Hill CS; Gehan E
    Cancer; 1974 Oct; 34(4):1328-32. PubMed ID: 4418930
    [No Abstract]   [Full Text] [Related]  

  • 58. Lesionalized therapy beyond personalized therapy in cancer management.
    Chung JK; Kim MJ; Youn H
    J Korean Med Sci; 2014 Oct; 29(10):1331-2. PubMed ID: 25368484
    [No Abstract]   [Full Text] [Related]  

  • 59. Intratumor BRAFV600E heterogeneity and kinase inhibitors in the treatment of thyroid cancer: a call for participation.
    Vitale M
    Thyroid; 2013 Apr; 23(4):517-9. PubMed ID: 23398043
    [No Abstract]   [Full Text] [Related]  

  • 60. Frontiers in thyroid cancer: December 2009.
    Cheng SY; Ringel MD
    Thyroid; 2009 Dec; 19(12):1297-8. PubMed ID: 20001712
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.